| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: =98.78%
| Targets |
Natural quinazolinone alkaloid
|
|---|---|
| ln Vitro |
In this study, the antimalarial activities of the synthesized febrifugine and isofebrifugine, and their antipodes, were examined. It was revealed that the activities and selectivities of natural febrifugine and isofebrifugine were much higher than those of the antipodes[1].
|
| Enzyme Assay |
Antimalarial Assay: [1]
In vitro Antimalarial Activity of Febrifugine, Isofebrifugine, and Their Enantiomers: The following procedures were used for assay of antimalarial activity. Various concentrations of compounds in ethanol were prepared. A 5 μL amount of each solution was added to individual wells of a multidish 24 wells arrangement. Erythrocytes with 0.3% parasitemia were added to each well containing 995 μL of culture medium to give a final hematocrit level of 3%. The plates were incubated at 37 °C for 72 h in a CO2−O2−N2 incubator (5% CO2, 5% O2, and 90% N2 atmosphere). To evaluate the antimalarial activity of a compound, we prepared thin blood films from each culture and stained them with Giemsa. A total of 10 000 erythrocytes per one thin blood film were examined by microscopy. All of the test compounds were assayed in duplicate at each concentration. Drug-free control cultures were run simultaneously. All data points represent the mean of three experiments. The EC50 value refers to the concentration of the compound necessary to inhibit the increase in parasite density at 72 h by 50% of control.[1] |
| Cell Assay |
Toxicity against Mammalian Cell Line.[1]
FM3A cells grew with a doubling time of about 12 h. Prior to exposure to drugs, cell density was adjusted to 5 × 104 cells/mL. A cell suspension of 995 μL was dispensed to the test plate, and compounds at various concentrations suspended in ethanol (5.0 μL) were added to individual wells of a multidish 24 well arrangement. The plates were incubated at 37 °C in 5% CO2 atmosphere for 48 h. All the test compounds were assayed in duplicate at each concentration. Cell numbers were measured using a microcell counter CC-130. All data points represent the mean of three experiments. The EC50 value refers to the concentration of the compound necessary to inhibit the increase in cell density at 48 h by 50% control. |
| References | |
| Additional Infomation |
Isofebrifugine is a member of quinazolines.
Isofebrifugine has been reported in Hydrangea macrophylla and Hydrangea febrifuga with data available. |
| Molecular Formula |
C16H19N3O3
|
|---|---|
| Molecular Weight |
301.3404
|
| Exact Mass |
301.143
|
| CAS # |
32434-44-9
|
| PubChem CID |
9851693
|
| Appearance |
White to off-white solid
|
| Density |
1.48±0.1 g/cm3 (20 ºC 760 Torr)
|
| Boiling Point |
519.8±58.0 °C(Predicted)
|
| Melting Point |
138-139 ºC
|
| Source |
Chinese medicinal plant, Chang Shan (Dichroa febrifuga)
|
| LogP |
0.954
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
483
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C[C@H]2[C@H](CC(O2)(CN3C=NC4=CC=CC=C4C3=O)O)NC1
|
| InChi Key |
YLYLCQRQSRDSQR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H19N3O3/c20-15-11-4-1-2-5-12(11)18-10-19(15)9-16(21)8-13-14(22-16)6-3-7-17-13/h1-2,4-5,10,13-14,17,21H,3,6-9H2
|
| Chemical Name |
3-[(2-hydroxy-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridin-2-yl)methyl]quinazolin-4-one
|
| Synonyms |
Isofebrifugine; 32434-44-9; 3-[[(3aS,7aS)-2-hydroxy-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridin-2-yl]methyl]quinazolin-4-one; 3-[(2-hydroxy-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridin-2-yl)methyl]quinazolin-4-one; ISOFEBRIFUGINE (B604866K055); CHEMBL105789; C10698; SureCN12033795;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3185 mL | 16.5926 mL | 33.1851 mL | |
| 5 mM | 0.6637 mL | 3.3185 mL | 6.6370 mL | |
| 10 mM | 0.3319 mL | 1.6593 mL | 3.3185 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04553705 | Completed | Drug: Active Comparator Drug: Omega 3/Nigella Sativa Oil |
Covid19 Immunodeficiency |
Beni-Suef University | September 20, 2020 | Phase 2 Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA